Flunarizine acts as a selective calcium channel antagonist for migraine prophylaxis. It prevents cellular calcium overload, thereby modulating neuro-vascular contractions and reducing the frequency and intensity of recurrent vasomotor-related discomfort.
Targeting neuronal calcium channels, this calcium-channel blocker helps modulate vestibular excitability. The compound belongs to the diphenylpiperazine class and acts as a selective inhibitor of calcium influx in nerve cells. Its primary therapeutic role involves reducing the frequency and intensity of dizziness-related episodes. The substance appears as the active ingredient in medications marketed under the name Flunarizine.
Appearing in both generic tablets and branded capsules, the active compound is incorporated into products labeled Flunarizine throughout Singapore. Tablet strengths commonly range from 5 mg to 10 mg, while some formulations include a sustained-release profile for once-daily dosing. In the local market, pharmacists dispense both locally manufactured generics and imported branded versions, all subject to the Health Sciences Authority’s regulatory oversight. Consumers obtain these products via prescriptions from qualified clinicians, though the overview does not address prescribing details.
Alleviating recurring dizziness, the agent finds use in several neurological contexts. It assists patients experiencing vestibular migraine, a condition marked by episodic vertigo coupled with migraine features. Motion-sickness sufferers may benefit when other remedies have proved insufficient. Individuals with episodic vertigo of uncertain origin sometimes receive this therapy to manage symptom spikes. In addition, it is occasionally employed for certain types of migraine where traditional triptans are unsuitable.
Reducing calcium influx into nerve cells, the substance steadies overactive signaling pathways that trigger abnormal vestibular firing. By dampening excitatory neurotransmission, it helps lower the threshold for triggering vertigo. The effect is gradual, often requiring several days before patients notice symptom improvement. This mechanism allows the compound to complement other supportive measures such as balance exercises.
Mild fatigue and a dry mouth may appear during the first weeks of therapy. These effects usually resolve without medical intervention.
Rarely, patients report mood changes or signs of liver irritation that warrant prompt medical attention. Immediate evaluation is advised if severe depression or jaundice develop.
Pregnant individuals, people with known severe liver impairment, and those with a documented hypersensitivity to diphenylpiperazine agents should avoid this medication. Caution is also recommended for individuals with a history of depressive disorders.
Concurrent use of alcohol or central-nervous-system depressants can enhance sedation. Certain antihistamines and other migraine preventives may alter the drug’s effectiveness. Users should refer to the specific medication’s insert for a complete interaction list.
Storing tablets in a cool, dry place protects potency until the expiration date printed on the package. Short-term courses often target acute vertigo episodes, while chronic regimens may extend for several months to maintain symptom control. Formulation differences, such as immediate versus sustained release, influence the optimal treatment length. For detailed usage, dosing, and administration, refer to the specific medication's clinical information.
This educational overview of Flunarizine is not medical advice. Individual medicines named Flunarizine differ in strength, formulation, and instructions. No liability is assumed for any clinical application. Patients should review the medication’s labeling and discuss use with a qualified healthcare professional.
